Monte Rosa Therapeutics, Inc. Convertible Preferred Stock, Shares Issued upon Conversion
Monte Rosa Therapeutics, Inc. (GLUE) had Convertible Preferred Stock, Shares Issued upon Conversion of 31.07 million shares as of 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Notes › Equity
us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion · last filed 2022-03-29
- 2021-12-31: Convertible Preferred Stock, Shares Issued upon Conversion 31.07M shares.
- 2021-06-30: Convertible Preferred Stock, Shares Issued upon Conversion 31.07M shares.
| Period end | Convertible Preferred Stock, Shares Issued upon Conversion |
|---|---|
| 2021-12-31 | 31.07M shares 10-K · filed 2022-03-29 |
| 2021-06-30 | 31.07M shares 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |